دورية أكاديمية
Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain.
العنوان: | Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain. |
---|---|
المؤلفون: | Espinosa J; Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., González-Larriba JL; Hospital Clínico San Carlos, Madrid, Spain., Maroto P; Hospital Sant Pau, Barcelona, Spain., Méndez-Vidal MJ; Hospital Reina Sofía, Córdoba, Spain., Díaz-Cerezo S; GSK España, Tres Cantos, Spain. |
المصدر: | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2014 Nov; Vol. 17 (7), pp. A632-3. Date of Electronic Publication: 2014 Oct 26. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Publication: Jan./Feb. 2011- : New York : Elsevier Original Publication: Malden, MA : Blackwell Science, c1998- |
تواريخ الأحداث: | Date Created: 20160521 Date Completed: 20160610 Latest Revision: 20160521 |
رمز التحديث: | 20231215 |
DOI: | 10.1016/j.jval.2014.08.2265 |
PMID: | 27202249 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1524-4733 |
---|---|
DOI: | 10.1016/j.jval.2014.08.2265 |